Metal Oxide Nanoparticle Cancer Cell Lysis via Biocatalyst Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional cancer therapies face challenges in targeting cancer cells effectively while minimizing side effects, as they often result in premature release of toxic remedies and have numerous side effects despite targeted drug delivery.
Innovation Solution
Metal oxide nanoparticles (MOX NPs) are developed with a cancer recognition antibody and a biocatalyst coupled via a bidentate ligand, which, in the presence of a light emitting compound and adenosine triphosphate (ATP), generate reactive oxygen species to lyse cancer cells in situ, minimizing damage to healthy cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drugs are used for cancer treatment, then therapeutic effect is achieved, but numerous side effects occur and toxic remedies are prematurely released
Solution Approach 1:
The therapeutic agent is segmented into a nanoparticle system with distinct functional components: a metal oxide nanoparticle core for controlled activation, a biocatalyst component for light generation, and a cancer recognition component for targeting. This segmentation allows the toxic therapeutic remedy to be contained and only released when all components work together at the target site, preventing premature release and reducing side effects while maintaining therapeutic effect.
2Object-affected harmful factors
If targeted drug delivery is used to deliver therapeutic to cancer cells, then side effects are reduced, but premature release of toxic remedies still occurs
Solution Approach 1:
The nanoparticle is pre-equipped with a cancer recognition component that binds to cancer cell surfaces during circulation. This preliminary targeting action ensures the nanoparticle is positioned at the correct location before activation occurs. The biocatalyst and light-emitting compound are also pre-positioned on the nanoparticle, ready to generate light upon reaching the target, ensuring controlled activation only at the cancer site and preventing premature release.
3Quantity of substance
If carriers relying on pH change or EPR effect are used, then drug accumulation at cancer site is achieved, but precise control of drug release timing is limited
Solution Approach 1:
The passive physical mechanisms (pH change, EPR effect) are replaced with an active biochemical system. The biocatalyst on the nanoparticle catalyzes a light-emitting reaction that generates photons to activate the metal oxide nanoparticle core. This substitution provides precise temporal control over drug release timing, as the therapeutic is released only when the biocatalyst is activated by its substrate, rather than relying on uncontrolled passive accumulation mechanisms.
4Measurement precision
If conventional targeted therapy is used, then cancer cells are targeted, but off-target effects still occur due to premature release
Solution Approach 1:
Multiple functions are merged into a single integrated nanoparticle system: cancer cell targeting, light generation, and therapeutic activation. The cancer recognition component ensures the nanoparticle binds to the correct target, the biocatalyst generates light only when substrate is present, and the metal oxide core releases therapy only upon light activation. This merging of functions ensures that all conditions for therapy release are met simultaneously at the target site, eliminating off-target effects while maintaining high targeting accuracy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MOX NPs enable targeted and efficient cancer cell lysis with minimal side effects by using ATP produced by cancer cells to generate photons, transforming the nanoparticles into an excited state that produces reactive oxygen species, effectively triggering apoptosis in cancer cells while sparing healthy cells.
Implementation Method 1
the biocatalyst is structured to selectively catalyze the oxidation of a light emitting compound to produce photons
Implementation Method 2
The photons transform the MOX NPs into an excited state such that the MOX NPs generate reactive oxygen species (ROS) in the vicinity of the cancer cells in the excited state
Data Source
AI summary
A nanostructure comprises a MOX NP and a bidentate ligand on a surface of the MOX NP. A cancer recognition molecule is covalent coupled to the surface of the MOX NP via the bidentate ligand. A biocatalyst is also coupled to the surface of the MOX nanoparticle via the bidentate ligand. The cancer recognition molecule includes a structure configured to selectively recognize a corresponding antigen on a surface of a cancer cell and bind to the antigen. The biocatalyst is structured to selectively catalyze the oxidation of a light emitting compound to produce photons. The photons transform the MOX NPs into an excited state such that the MOX NPs generate reactive oxygen species (ROS) in the vicinity of the cancer cells in the excited state. The reactive oxygen species lyse or cause apoptosis in the cancer cells in situ. The biocatalyst includes luciferase and the light emitting compound includes luciferin.